I migliori medici per il trattamento di Leiomiosarcoma - TOP-5 medici

Il Prof. Ofer Merimsky dirige l'Unità di Oncologia dei Tessuti Molli e delle Ossa presso il Sourasky Medical Center, con esperienza specializzata nel trattamento dei sarcomi.

• Oltre 25 anni di esperienza focalizzata su sarcoma e tumori ossei
• Membro della Facoltà ESMO per i sarcomi dei tessuti molli e delle ossa
• Ha completato un fellowship presso l'Institut Gustave Roussy a Parigi
• Ha pubblicato una vasta ricerca sull'immunologia tumorale e sui sarcomi

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Il medico è un esperto leader in ematologia e oncologia pediatrica, specializzato in disturbi del sangue e cancro osseo (sarcoma) nei bambini. Attualmente, il medico è direttore del dipartimento di ematologia oncologica pediatrica presso il Sourasky Medical Center di Tel Aviv ed è un pediatra senior presso il Dana Children's Hospital. Il medico coordina il trattamento del cancro osseo e del sarcoma dei tessuti molli, gestisce i disturbi della coagulazione del sangue e supervisiona l'ematologia nei neonati prematuri. Il medico è membro dell'Associazione Israeliana di Emato-Oncologia Pediatrica (ISPHO).

Il medico si è laureato presso l'Università Ben-Gurion e si è specializzato in medicina pediatrica presso il Kaplan Medical Center, con ulteriore specializzazione in ematologia e oncologia pediatrica presso il Schneider Children's Medical Center. Ulteriore formazione è stata completata in oncologia ossea e dei tessuti molli presso l'Istituto Ortopedico Rizzoli in Italia.

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.